Oncotarget’s Rapid Publishing Lets Researchers Expand Upon Current Research

Oncotarget’s popularity, the bi-weekly journal which is published by Impact Journals has more papers on oncology published in 2015 that any other journal that year, is due to the fact that researchers want to make an impact by having their papers published quickly, so that others may benefit from, and expand upon, their current work.

Although Oncotarget’s primary focus is a multidisciplinary approach to cancer and aging research, endocrinology, metabolism and pharmacology papers are also accepted. Papers on all subjects are published online under a Creative Commons Attribution License, where the journal’s online visitors may read and download the articles to use as long as they cite the source and the authors if they use the paper.

Despite Oncotarget’s ability to publish quickly, they have a stringent peer review process. Papers are judged on scientific merit with unbiased analysis by at least two reviewers, but typically, three to five, who have expertise in the paper’s subject. Additionally, an editor-in-chief must grant final approval, based on the editor’s comments. Mikhail V. Blagosklonny and Andrei V. Gudkov serve as Oncotarget’s editors-in-chief. Submissions are peer reviewed in parallel, as opposed to being sent from one reviewer to another, which speeds up the process, allowing research to be published quickly. Oncotarget takes advantage of modern technology to hasten the review process, and papers are sent to editors immediately, even on weekends.

Oncotarget’s open-access publishing policy has one primary advantage; it makes extraordinary scientific research available quickly, with charge, to all who may benefit from the researcher’s efforts. Increasing scholarly communication in the fields of cancer and aging will no doubt benefit more than fellow researchers in the future.

Follow Oncotarget on Twitter.

Rutgers Cancer Institute Establishes New Chair Named for Omar Boraie (Updated 2017)

UPDATE January 20th 2017 — Trust donates to Rutgers Cancer Institute

UPDATE: 21st November 2016Rutgers Cancer Institute researcher receives grant to explore cell pathway in triple-negative breast cancer


Rutgers University just announced the addition of the Omar Boraie Chair as part of the 18 Chair Challenge that was designed to bring more research opportunities to the University. The Omar Boraie Chair is in Genomic Science, and is named for the New Brunswick developer who has donated the funds to pay for the research in precision medicine that Rutgers science research need.

NewsWise published a piece about the donor and the new chair that has been created in his name, as well as the type of research that will be funded as part of this donation. The challenge is unique because with each chair that is created, an anonymous donor is matching the initial 1.5 million dollars in order to bring the total of each chair funded to 3 million dollars. Developer Omar Boraie has long been a supporter of the health development, so when the challenge was announced he knew that he had to further support the Cancer Institute and the scientific research that the conduct.

The chair that Omar Boraie is funding will provide funds for genomic science, especially precision medicine. This specialized area of research looks at the way in which doctors and healthcare providers treat cancer. Different therapies can be tested out as doctors are able to track and treat tumors at the genomic level, which can entirely change treatment and recovery for patients living with the disease. This type of research in cancer is hoped to produce better outcomes for patients and be the future of cancer treatment.

The advances that have already been made at Rutgers are promising, and being used by other centers that are now seeing the value in genomic science. Rutgers researchers are able to use the funds provided by the chair challenge to further develop the techniques that they use as well as develop new therapies and studies. Individual cancer therapy creation can be the key to treating patients in the best possible way in the future, offering a specific type of treatment based on the exact type of tumor and cancer that each patient has. The uniqueness of each type of cancer requires us to learn as much as we can about each so that we can better treat them, and this is something that Rutgers understands. Boraie understands this as well and has said that he hopes his donation is able to help doctors find some answers into the treatment of cancer.